Stocks · News reference
JP Morgan analyst Casey Woodring maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $315 to $360.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated
Read original at benzingaCitigroup analyst Brendan Digan maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $315 to $365.
Read original at benzingaPiper Sandler analyst David Westenberg maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $249 to $363.5.
Read original at benzingaStephens & Co. analyst Mason Carrico maintains Natera (NASDAQ:NTRA) with a Overweight and raises the price target from $305 to $350.
Read original at benzinga